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Abstract
Twenty years ago, the main barriers to successful cancer pain management were poor assessment by
physicians, and patients’ reluctance to report pain and take opioids. Those barriers are almost exactly the
same today. Cancer pain remains under-treated; in Europe, almost three-quarters of cancer patients
experience pain, and almost a quarter of those with moderate to severe pain do not receive any
analgesic medication. Yet it has been suggested that pain management could be improved simply by
ensuring that every consultation includes the patient’s rating of pain, that the physician pays attention to this
rating, and a plan is agreed to increase analgesia when it is inadequate. After outlining current concepts of
carcinogenesis in some detail, this paper describes different methods of classifying and diagnosing cancer
pain and the extent of current under-treatment. Key points are made regarding cancer pain management.
Firstly, the pain may be caused by multiple different mechanisms and therapy should reflect those
underlying mechanisms – rather than being simply based on pain intensity as recommended by the
WHO three-step ladder. Secondly, a multidisciplinary approach is required which combines both
pharmacological and non-pharmacological treatment, such as psychotherapy, exercise therapy and
electrostimulation. The choice of analgesic agent and its route of administration are considered, along
with various interventional procedures and the requirements of palliative care. Special attention is paid to the
treatment of breakthrough pain (particularly with fast-acting fentanyl formulations, which have
pharmacokinetic profiles that closely match those of breakthrough pain episodes) and chemotherapy-
induced neuropathic pain, which affects around one third of patients who receive chemotherapy. Finally,
the point is made that medical education should place a greater emphasis on pain therapy, both at
undergraduate and postgraduate level.
Introduction
In a recent pan-European survey of cancer patients, the most common reason for
the initial consultation that led to the cancer diagnosis was pain (Figure 1)1.
Studies have found that pain is experienced by 25–30% of patients with recently
diagnosed cancers2, by over 80% of patients with advanced metastatic disease3,
and that approximately 50% of hospitalized cancer patients experience
untreated pain during the last 3 days of life4. Importantly, the impact of this
pain on the quality of life can be devastating; cancer patients with pain report
significantly lower levels of performance status and higher levels of total mood
disturbance than those who are pain-free, as well as significantly more anger,
fatigue, depression, confusion, and lethargy5. However – and despite the fact
that World Health Organization (WHO) guidelines for the management of
cancer pain were published more than two decades ago6 – there is a substantial
body of evidence which indicates that the treatment of cancer pain is often
suboptimal1,7–9.
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Consensus points
The impact of cancer pain on quality of life can be devastating.
The treatment of cancer pain is often suboptimal.
The CHANGE PAIN Advisory Board of leading pain specialists from
Europe and the USA has met regularly since 2009 to discuss issues related to
the physiology and treatment of pain. Its main objectives are to increase the
understanding of pain among the wider medical community, and to improve
pain management by disseminating its conclusions and providing guidance to
other clinicians. On March 30th and 31st, 2012, the Board met in Du¨sseldorf to
review various aspects of the development and current treatment of cancer pain,
and then considered specific topics in more detail.
Development of cancer and cancer pain
The neurobiology of cancer pain is best understood by summarizing current
concepts of carcinogenesis. The initial change is a number of mutations occur-
ring in a cell over time. These may be caused by hereditary or biological factors,
or by exposure to physical or chemical agents, and they have a cumulative effect.
Certain types of gene – such as proto-oncogenes and tumor-suppressor genes –
play a key role in the transformation of a normal cell into a cancer cell, which
ignores signaling mechanisms that instruct it to stop dividing, become
specialized, or undergo apoptosis10. Typically, this is followed by pre-malignant
cellular proliferation which is usually reversible and may include: hyperplasia
(abnormal increase in the number of cells), hypertrophy (abnormal increase in
the size of cells), or dysplasia (alteration in the size, shape and organization of the
cellular components of a tissue). These cells are generally well differentiated and
function similarly to the tissue from which they arose. Progression to ‘cancer in
situ’ and then invasive cancer is accompanied by a gradual change in appearance
and loss of physiological functions, as the cells divide haphazardly and accumu-
late into a non-structured tumor. These later stages are almost always irreversible
and are characterized by the capacity to invade healthy tissue, both locally and
in distant organs, via blood and lymphatic vessels.
Some cancer pain arises from within the cancer microenvironment11.
The key cellular components here are primary afferent nociceptors, immune
cells and the cancer cells, which produce and secrete mediators that modulate
nociception. These mediators include endothelin-1 (ET-1), protons, proteases,
nerve growth factor (NGF), bradykinin and tumor necrosis factor alpha (TNFa),
which have an effect on primary afferent nociceptors to produce pain11.
Low pH is characteristic of the cancer microenvironment, reflecting the
elevated metabolic rates and anaerobic conditions that occur with carcinogen-
esis. This acidosis induces the expression of acid-sensing ion channels (ASICs)
and is a well established cause of pain11. ET-1 produces nociceptive behavior12,13
and drives cancer pain14 by binding to G-protein coupled receptors that
differentially affect opioid release from tumors. For example, there is evidence
that an allelic substitution of adenine by guanine in position 118 (A118G) of the
m-opioid receptor gene (OPRM1) has an effect on angiogenesis and tumor
growth15. The nociceptive effect of protons is produced by direct activation
of the transient receptor potential vanilloid-1 (TRPV-1) channel, a
Ca2þ-permeable ionotropic receptor. Proteolytic activity plays a major role in
carcinogenesis and cancer pain; protease activated receptors (PARs) are present
on primary afferent nociceptors and are activated either directly by proteases or
Current Medical Research & Opinion Volume 30, Number 9 September 2014
1896 Pain in the cancer patient Mu¨ller-Schwefe et al. www.cmrojournal.com ! 2014 Informa UK Ltd
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 H
els
ink
i] 
at 
22
:22
 11
 Ja
nu
ary
 20
16
 
by their peptide products. NGF is normally secreted to
promote the local growth and survival of afferent sensory
neurons, but its secretion into the microenvironment by
cancer cells leads to a number of changes that produce
pain, including modulation of inflammatory cell activity.
Certain cancers secrete kallikrein, which increases the
concentration of bradykinin in the microenvironment16.
Bradykinin appears to have a direct nociceptive effect in
cancer pain, since blockade of the bradykinin B1 receptor
reduces bone cancer pain17, but it also induces increased
expression and secretion of ET-118. High levels of proin-
flammatory cytokines are produced in cancer and TNFa
stimulates immune cells, which can produce nociceptive
agents that interact with primary afferent nociceptors19. In
addition, a direct local role for TNFa in the production of
both mechanical and heat hyperalgesia has been demon-
strated in animal models20,21.
Inflammation is a key component of the tumor
microenvironment and inflammation-mediated tumor
progression is produced by transcription factors, cytokines,
chemokines and infiltrating leukocytes22. By directly or
indirectly downregulating DNA repair pathways and
cell cycle checkpoints, these inflammatory mediators
produce a genomically heterogenous population of
expanding cells naturally selected for their ability to
proliferate, invade and evade host defenses. A particularly
insidious form of tumor growth is perineural invasion;
i.e. the spread and proliferation of cancer within a
nerve. This process is associated with NGF23, linked to
both pain and recurrence following surgical resection24,25,
and also indicates poor prognosis and reduced survival
rates25,26. Early symptoms may include pain, burning sen-
sations, paresthesias, numbness and formication27,
although the patient may be asymptomatic at first.
Motor weakness is a late sign27, while complete denerv-
ation may produce muscle atrophy. Perineural involve-
ment is emerging as an important pathological feature of
many malignancies, including those of the pancreas, colon
and rectum, prostate, head and neck, biliary tract, and
stomach28.
Often, the first symptom for which patients consult a
physician is pain from bone metastasis29. This is a multi-
step process which includes the following sequence of
events: (I) tumor growth, detachment of cancer cells and
invasion of the tissue stroma; (II) neoangiogenesis; (III)
escape from the tissue by intravasation; (IV) survival in the
circulation; (V) chemoattraction and arrest (docking and
locking) in the bone marrow endothelial vessel wall; (VI)
extravasation; and (VII) establishment of the metastatic
microenvironment via the cross-talk between the cancer
and bone cells30–32. Cyclooxygenase-2 (COX-2) is
thought to play a major role in this process;
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Figure 1. Reasons for consulting a healthcare professional that led to a diagnosis of cancer1. By permission of Oxford University Press.
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over-expression leads to increased tumor formation and
pharmacological suppression of COX-2 inhibits
metastasis.
Pain may arise not only from the presence of many
different factors in the microenvironment, as previously
described, but also from one or more of the following:
nerve root infiltration, nerve compression, microfractures,
stretching of the periosteum, increased intraosseous
pressure and muscle spasm33. However, a significant
portion of the pain seems to be related to osteoclastic
bone resorption34, and animal studies have demonstrated
the involvement of both peripheral sensitization, as a
result of physiological and morphological changes to
primary afferent fibers35, and central sensitization, by
augmentation of excitatory synaptic transmission in the
substantia gelatinosa which is mediated via Ad and C
fibers36.
Classification of cancer pain
The clinical presentation of cancer pain can vary consid-
erably, depending upon the histology of the cancer cells,
the site of the primary neoplasm, and the location of any
metastases. The pain may be classified in a number of
different ways; for example, according to the type of
pain, its relation to the cancer, the presence of pain
syndromes (e.g. bone pain syndromes, visceral pain
syndromes, post-chemotherapy pain syndromes), or the
incidence and duration.
Pain type
In addition to the distinction between acute and chronic
pain, pain syndromes can be divided into three classes
according to their clinical features and etiology37.
Nociceptive pain is caused by the activation of peripheral
Ad and C fibers (high-threshold nociceptor neurons) that
respond only to noxious thermal, mechanical or chemical
stimuli (e.g. pinprick, ligamentous stretch). Adaptive and
biologically useful, it contributes to survival by protecting
the organism from injury and promoting healing when
injury has already occurred. It is usually short-lived and
resolves once healing is complete38. Other conditions in
which it is seen include arthritis, sports injuries and post-
operative pain39. There are two subtypes of nociceptive
pain: somatic and visceral. Somatic pain involves the
skin, bones and soft tissues, and characteristically is
easily localized, stabbing or boring in character, and
movement-dependent. Visceral pain, which involves par-
enchymatous organs, hollow viscera and the peritoneum, is
dull, difficult to localize and colicky in nature. Patients
often describe it as a diffuse or ‘pressure-type’ sensation.
Inflammatory pain is essentially pain which occurs
when active peripheral inflammation is detected by
nociceptors, and leads to sensitization of the nociceptive
system (e.g. joint pain such as facet pain).
The third class – neuropathic pain – is not adaptive, has
no protective function, and represents a disease state of the
nervous system. It may be defined as ‘pain arising as direct
consequence of a lesion or disease affecting the somato-
sensory nervous system’. Essentially, a maladaptive plasti-
city alters nociceptive signal processing, so that responses
to noxious and innocuous stimuli are enhanced, and pain is
felt in the absence of stimuli (e.g. radicular pain)40. The
pain may be perceived as shooting, lancinating, ‘electric
shock-like’ or burning, and may occur spontaneously.
Positive signs, such as allodynia, hyperalgesia and hyper-
pathia may be accompanied by negative signs such as the
loss of touch, vibration, pinprick, or thermal hypoalgesia.
Neuropathic pain is typically present in cases of posther-
petic neuralgia, peripheral diabetic neuropathy and
multiple sclerosis.
Many patients with chronic pain experience a combin-
ation of different pain types – a condition sometimes
referred to as mixed pain syndrome41. For the sake of sim-
plicity, however, in clinical practice nociceptive and
inflammatory pain are grouped under the term nociceptive
pain, and a distinction is only made between nociceptive
and neuropathic pain. Cancer pain may be nociceptive,
neuropathic, or a combination of both types.
Relation to cancer
This classification system divides cancer pain into four
categories. Firstly, cancer-related pain is directly linked
to carcinogenesis and is most often caused by either com-
pression – when a tumor physically presses on an organ or
body part – or by the infiltration of hollow organs,
soft tissue, bones, or nerves. Soft tissue infiltration causes
localized pain as a result of tissue destruction and the
infiltration of pain-sensitive structures such as fascia or
tendons. Metastasis to the viscera is frequently seen in
cases of lung and breast cancer, and this produces poorly
localized, deep-seated pain in the chest, abdomen, or
pelvis. Referred painmay also be present when a peripheral
nerve is involved. Between 60% and 90% of cancer
patients experience cancer-related pain42.
Cancer-induced bone pain (CIBP) is an important
example of cancer-related pain, which a review of
26 studies found to be undertreated in 43% of patients
(range 8–82%)43. It often results in hospice or hospital
admission and is associated with a reduced quality of life,
increased psychological distress and decreased physical
and social functioning44. Notably, the extent and location
of bone metastases do not necessarily correlate with pain
intensity45; patients with widespread metastases may have
minimal pain, and patients with few metastases may
experience severe pain.
Current Medical Research & Opinion Volume 30, Number 9 September 2014
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The second category, cancer-associated pain, is
only indirectly linked to the patient’s cancer; for
example, acute pain from herpes zoster or chronic
post-herpetic neuralgia (PHN) due to tumor growth
induced impairment of the patient’s immune system,
back pain as a result of being confined to bed for long
periods of time, or coughing caused by lung cancer that
triggers low back pain. This affects 5–20% of cancer
patients42.
Treatment for the disease – including diagnostic inves-
tigations, surgery, chemotherapy, or radiotherapy – leads
to therapy-related pain in 10–25% of patients42. Surgery
may produce pain as a direct result of tissue injury or indir-
ectly following scar formation, and neuropathic pain may
follow any surgical procedure. Chemotherapy may induce
painful polyneuropathy and/or mucositis. Oral mucositis
may produce ulceration so severe that the patient is
unable to tolerate food or fluids, delaying treatment and
limiting the effectiveness of cancer therapy. Radiotherapy
can cause painful inflammation of any mucous
membranes that are irradiated. Other examples of ther-
apy-related pain include myelopathy after treatment of
the spinal cord, and neuropathy, which may develop
months or even years after irradiation of the brachial or
lumbar plexus.
The final category is cancer-independent pain, in
which pain is caused by conditions that were present
before the cancer diagnosis or arise independently of
carcinogenesis. Conditions such as rheumatoid arthritis
and migraine are responsible for this category of pain in
3–10% of cancer patients42.
Cancer pain syndromes
Approximately three-quarters of patients with chronic
cancer pain have syndromes directly related to the neo-
plasm46. These may be subdivided into neuropathic
syndromes (e.g. cranial neuralgias, peripheral neuropa-
thies), visceral nociceptive syndromes (e.g. hepatic disten-
sion syndrome, peritoneal carcinomatosis), and somatic
nociceptive syndromes (e.g. tumor-related bone pain,
vertebral syndromes). Most of the remainder have
syndromes caused by antineoplastic treatment. Again,
these can be subdivided into those caused by chemother-
apy (e.g. peripheral neuropathy, complex regional
pain syndrome), radiotherapy (e.g. chronic radiation
myelopathy, burning perineum syndrome), or surgery
(e.g. post-mastectomy pain syndrome, post-thoracotomy
pain syndrome and frozen shoulder, post-amputation
pain). Identifying these syndromes can guide
clinical assessment and treatment, clarify prognosis,
allow preventive care, and provide reassurance to patients
who interpret their pain as an indication of cancer
progression46.
The complex, multidimensional nature of cancer pain
presents challenges for pain classification, but the
Edmonton Classification System for Cancer Pain
(ECS-CP) has been developed to detect the presence of
complex pain syndromes and guide the management of
patients with advanced cancer47. It uses five features –
pain mechanism, incident pain, psychological distress,
addictive behavior and cognitive function – and simultan-
eously integrates them within a cohesive framework to
forecast the likely time to stable pain control, analgesic
regimen and opioid dosage. Its predictive value has been
confirmed in a study involving over 1000 patients from 11
palliative care centers in six different countries47. A pain
syndrome was found to be present in 86% of subjects.
Younger age, neuropathic pain, incident pain,
psychological distress and pain intensity were independ-
ently associated with days to achieve stable pain control.
Patients with neuropathic pain, incident pain, psycho-
logical distress or higher pain intensity required more
adjuvants and higher final opioid doses, in contrast to
those with addictive behavior who required only higher
final opioid doses47.
Incidence and duration
Following a recent study, a new clinically based classifica-
tion has been proposed which is based upon the temporal
characteristics and nature of the pain experience48.
Continuous pain alone, i.e. without any episodic increase
in intensity, was experienced by 11% of the patient
sample48. Intermittent or non-breakthrough pain (NBP)
alone was reported by 29%48. This may be defined as
episodic pain of any intensity without continuous pain
and in the absence of prescribed ‘around the clock’
(ATC) analgesics. The three categories of NBP are
incident, non-incident and mixed. Incident pain is
predictable and related to a specific precipitant, which
may be voluntary (e.g. eating) or involuntary (e.g. cough-
ing), whereas non-incident pain has no apparent
precipitating factor. Almost two-thirds (60%) of the
patients had periods of intermittent pain superimposed
upon continuous pain48. The episodic increase in
severity, or breakthrough pain (BP), has been defined
by Portenoy and Hagen as ‘‘a transitory exacerbation of
pain that occurs on a background of otherwise
stable pain in a patient receiving chronic opioid ther-
apy’’49. This is sub-divided similarly to NBP, but
some clinicians recognize a fourth category – end of dose
failure – although there is a lack of evidence for this clas-
sification50. Patients experience intermittent pain
that consistently occurs before a scheduled ATC dose,
and it usually indicates that the ATC dose should be
increased.
Current Medical Research & Opinion Volume 30, Number 9 September 2014
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Consensus point
The various, often combined, mechanisms and different
characteristics of continuous and breakthrough pain can
make cancer pain management difficult.
Cancer pain – prevalence, intensity, and
treatment
The European Pain in Cancer survey provided the first
robust pan-European epidemiological data on cancer
pain and its treatment in 20091. A total of 5084 adult
patients from 11 European countries and Israel, with a
wide range of cancers and at all stages of the disease,
took part in an initial telephone interview. From
these, 573 patients who had experienced pain several
times a week over the previous month, and with a
pain intensity of 5 on a 0–10 Numeric Rating Scale
(NRS), were randomly selected for a second in-depth
interview1.
The overall incidence of pain in the survey sample
(n¼ 4947) was 73%, and ranged from 53% in patients
with prostate cancer to 93% in patients with pancreatic
cancer (Figure 2)1. A striking variation was seen in the
proportion of patients reporting pain in different coun-
tries, from 43% in Sweden to 95% in Italy. However,
this may be caused by the types of cancer being
dissimilar from one country to another, and types with
the highest prevalence of pain (pancreas, bone, brain,
lymphoma, lung) being over-represented in some coun-
tries (Switzerland, Israel, Italy, UK, France, and
Ireland)1. Almost a quarter (23%) of the respondents
who reported an NRS score of 5 in this initial
survey were receiving no analgesic medication, including
19% of those patients who experienced pain of this
intensity daily or more frequently1.
Most patients who were selected for the second inter-
view reported that their pain was managed by either a
medical oncologist (42%) or a general practitioner
(19%), but the range of healthcare professionals who had
this responsibility was quite diverse (Figure 3)1. For the
majority (72%) of patients, their clinician asked about
their pain at most (16%) or all (56%) consultations.
However, more than a fifth (22%) were never, or only
occasionally, asked about their pain, while more than
half (55%) proactively described their pain at each con-
sultation, to ensure that it was taken into consideration1.
After prompting, 33% of patients recalled that their
clinician had used a pain scale to measure their pain, but
there were major differences between countries, with Italy
(70%), France (52%), and Ireland (40%) using these
instruments most frequently1.
Although all these patients (n¼ 573) had moderate
to severe pain, 11% were not receiving any analgesia
and a further 8% were taking only over-the-counter
(OTC) medication1. More than a quarter (28%) of
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Figure 2. Incidence of pain by cancer type (CRC¼ colorectal cancer, NHL¼ non-Hodgkin’s lymphoma, SCCHN¼ squamous cell cancer of the head and
neck)1. By permission of Oxford University Press.
Current Medical Research & Opinion Volume 30, Number 9 September 2014
1900 Pain in the cancer patient Mu¨ller-Schwefe et al. www.cmrojournal.com ! 2014 Informa UK Ltd
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 H
els
ink
i] 
at 
22
:22
 11
 Ja
nu
ary
 20
16
 
those whose pain was rated at NRS 7 (n¼ 241) were
not receiving strong opioids. Of the patient sample,
50% believed that their clinicians did not consider qual-
ity of life to be an important aspect of the overall care
plan, and 12% believed their clinicians did not under-
stand that pain was a problem. Substantial minorities
believed that their clinicians would rather treat their
cancer than their pain (38%) or did not know how to
treat moderate to severe cancer pain (26%). Large majo-
rities of those patients receiving prescription analgesics
(84%; n¼ 441) and of those receiving strong opioids 87%
(n¼ 183) rated their medication as ‘quite effective’ or ‘very
effective’1. However, breakthrough pain was common
among those receiving prescription medication, affecting
63%of the patients. The authors concluded that ‘‘poor care
of cancer pain is clearly unacceptably commonplace in
Europe’’1.
These results were supported by a recent survey which
found that the most significant barriers to successful cancer
pain management were almost exactly the same as 20 years
ago – poor assessment, patients’ reluctance to report pain
and to take opioids – and that efforts to improve
treatment have had little effect on oncologists’ attitudes
and practice51. It has been suggested that improving the
management of cancer-related pain could be as simple as
ensuring that every consultation includes the patient’s
rating of pain, that the oncologist pays attention to the
answer, and a plan is agreed to increase analgesia when it is
inadequate52.
Cancer pain management
General principles of treatment
The overall objective of treating cancer pain is to
achieve pain relief and the highest possible quality of life
for the patient. Therapy should address all elements of the
patient’s pain: cancer-related, cancer-associated, therapy-
related, and cancer-independent. Successful management
of these diverse types of pain requires a multidisciplinary
approach combining both pharmacological and non-
pharmacological treatment such as psychotherapy, exercise
therapy, massage and electrostimulation53,54. General
principles include the immediate relief of acute pain and,
if possible, preventing the development of chronic pain.
As pain can be caused by multiple different mechan-
isms, it is important that pain therapy reflects these under-
lying mechanisms55,56 and is not simply based on pain
intensity, as recommended by the WHO three-step
ladder. For example, bone metastases often produce a
high local concentration of prostaglandins, so NSAIDs
are generally effective against CIBP, because they act
partly by blocking prostaglandin biosynthesis.
Also, beyond the physical distress it causes, pain may be
accompanied by fear, anxiety, weakness, depression and
insomnia. By explaining the causes of pain and the treat-
ment options to the patient in straightforward terms, these
symptoms can be alleviated, quality of sleep improved, and
the patient’s capacity for participating in daily life
increased.
Neurologist, 1
Nurse/Specialist nurse, 1
Anaesthetist, <1
Radiation oncologist, <1
Physiotherapist, <1
Other, 5
None, 3
Don’t know, 1
Medical oncologist, 42
Obstetrician/gynaecologist, 1
Palliative care specialist, 2
Pain specialist, 3
Haematologist,4
General surgeon, 4
Medical doctor, 8
GP/Primary care provider, 19
Figure 3. Healthcare provider responsible for pain management1. By permission of Oxford University Press.
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Consensus points
The key factor in successful cancer pain management is
a thorough diagnostic assessment of the contributing
pain mechanisms.
This should be supported by effective inter-disciplin-
ary collaboration; better collaboration between pain
specialists and oncologists should increase the use of
multimodal pharmacotherapy and non-pharmaco-
logical treatment.
Choosing an appropriate pharmacological agent and
its route of administration are vitally important. Oral
administration is the most common and easiest route for
most patients with cancer pain. However, the analgesic
effect of the agent is largely dependent upon its rate of
absorption from the gastrointestinal tract, so pain relief
does not begin for 20–30 minutes. Furthermore, bioavail-
ability may be compromised by, for example, emesis and/or
first-pass hepatic metabolism. Transdermal patches are
non-invasive and can produce steady-state concentrations
in 12 hours, while the dose can be increased by simply
adding further patches57. Side effects may be less when
using this route and often limited to local irritation at
the site of application58,59, but absorption may be
decreased in patients who are cachectic (e.g. by about
50% in the case of fentanyl)60, and sweating may cause
problems with adhesion (nocturnal hyperhidrosis is a
common symptom in cancer patients). Intravenous or
subcutaneous administration is usually combined with a
patient-controlled analgesia (PCA) device to provide
better control over the analgesia than does a continuous
infusion57. The bioavailability of hydromorphone given
subcutaneously has been shown to be approximately 80%
in cancer patients, and steady-state plasma concentrations
are reached within 24 hours61.
Administering drugs into the intrathecal space is
becoming increasingly popular for treating patients with
intractable pain or intolerable side effects from systemic
analgesic treatments62. The advantages of administration
directly into the cerebrospinal fluid include a reduction of
systemic side effects and the use of lower drug dosages63.
For cancer pain, morphine is the agent most commonly
administered via this route, but other opioid and
non-opioid drugs are used in this way: for example, hydro-
morphone, fentanyl, clonidine, or ziconotide62. In review-
ing studies of intrathecal drug delivery, predominantly
with morphine, Smith et al. found strong evidence for
short-term improvement in cancer pain, and reasonably
strong evidence for the use of intrathecal analgesic therapy
in long-term cancer pain management64. Similarly, intra-
thecal ziconotide has been shown to provide clinically and
statistically significant analgesia in some patients with
refractory cancer pain63,65.
The first choice of analgesic is often a non-opioid; for
example, paracetamol or a nonsteroidal anti-inflammatory
drug (NSAID) such as ibuprofen or a cyclooxygenase II
(COX II) inhibitor. Non-opioids are effective against pain
caused by soft tissue and muscle infiltration, while
NSAIDs are particularly useful for treating pain caused
by bone metastases. This is because tumor cells often
produce a high concentration of prostaglandins in the
affected bone, and NSAIDs act partly by blocking prosta-
glandin biosynthesis66. However, some NSAIDs (but not
COX II inhibitors) can also delay blood clotting, so may be
best avoided in patients receiving anti-cancer drugs that
can cause severe thrombocytopenia.
Biophosphonates introduced the concept of disease-
modifying therapy for bone metastases, and increasing
knowledge of the interaction between cancer cells and
the bone matrix has led to the identification of new thera-
peutic targets67,68. These include compounds and
processes involved in cancer-induced bone desorption
(e.g. osteoprotegerin, RANK/RANKL interaction), in
the metastasis of cancer cells to bone (e.g. Src, nerve
growth factor), and also targets on nociceptors that innerv-
ate bone (e.g. TPRV1, Trk)67,68.
Opioids are highly effective for treating moderate to
severe cancer pain69: for example, in conditions such as
visceral cancer pain, as well as soft tissue and bone pain,
and pain caused by neural compression. Updated guide-
lines on the use of opioids for treating cancer pain have
been issued by the European Association for Palliative
Care (EAPC)70. Developed according to the Grading
of Recommendations Assessment, Development and
Evaluation system, the 16 evidence-based recommenda-
tions cover such topics as choice of opioid and the treat-
ment of side effects70. For example, immediate-release
formulations are much more flexible than long-acting
preparations, but evidence suggests that immediate-release
and extended-release oral formulations of morphine,
oxycodone, and hydromorphone can be used for dose titra-
tion, supplemented by immediate-release oral opioids as
required70. Also – possibly as a result of incomplete
cross-tolerance – patients receiving opioids who do not
achieve adequate analgesia and have severe or unmanage-
able side-effects may benefit from switching to an alterna-
tive opioid70. A common barrier to the use of opioids is fear
of addiction in both physicians and patients, but this
should not prevent their prescription in patients who
need them.
In addition, there is an increasing use of adjuvant drugs;
these are typically non-opioids that confer analgesic effects
in certain medical conditions, but primarily treat condi-
tions that do not involve pain. Examples such as tricyclic
antidepressants and anticonvulsants are commonly and
successfully used to manage pain in cancer patients71.
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A wide variety of non-intrathecal interventional pro-
cedures are available, which can be used alone or in com-
bination. These include epidural drug infusions,
sympathetic nervous system blockade, nerve blocks, ver-
tebroplasty and kyphoplasty, as well as more invasive and
even destructive neurosurgical procedures72. The specific
intervention should be determined on an individual basis,
taking into account the location and characteristics of
the pain, as well as the patient’s expectations and life
expectancy. Regional analgesic techniques are usually
considered first, because they do not compromise
neurological integrity, while ablative or neurodestructive
procedures – which have a narrow risk–benefit ratio –
should be deferred as long as possible72.
When patients have incurable, progressive and
advanced disease with limited life expectancy, palliative
care aims to alleviate the physical and emotional symp-
toms – as far as possible – during the final phase of life.
The main focus is on pain therapy and symptom control.
Radiotherapy is effective in treating pain not adequately
controlled by analgesics, especially pain arising from
skeletal metastases; 50%–80% of patients experience
improvement in their pain, and 20%–50% of treated
patients have complete pain relief73–75. As life expectancy
is limited, radiotherapy schedules should provide max-
imum short- and long-term patient benefit consistent
with minimum associated morbidity and disruption of
patients’ lives. To this end the relative efficacy of single
and multiple treatment fractions have been investigated,
but no firm conclusions have been drawn. Common dosage
regimens include 30Gy in 10 fractions, 20Gy in 5 frac-
tions, and a single fraction of 8Gy. Palliative care also
includes providing psychosocial support to both the
patient and relatives, in order to maintain the patient’s
quality of life and allow him or her to die with dignity.
This generally requires co-operation between physicians
from various disciplines, nursing staff, and other profes-
sions involved in the treatment plan.
Breakthrough cancer pain
Breakthrough cancer pain (BTCP) occurs in patients who
have persistent pain (i.e. present for 12 hours per day)
which is stable and adequately controlled by ATC
analgesic medication76,77. It comprises a transitory exacer-
bation that requires assessment and targeted treatment
independent of the baseline pain76,77, and is highly preva-
lent among patients with cancer pain. In one prospective
survey, 64% of patients reported BTCP of severe or
excruciating intensity49. In addition, BTCP predicts
more severe pain, pain-related distress and functional
impairment, and relatively poor quality of life78.
BTCP may be divided into two categories: incident and
spontaneous77,79. Incident BTCP is related to a specific
identifiable cause which may be volitional (precipitated
by a voluntary act such as walking), non-volitional
(precipitated by an involuntary act such as coughing), or
procedural (precipitated by a therapeutic intervention
such as wound dressing). Spontaneous or idiopathic
BTCP occurs unexpectedly and cannot be predicted.
It should be noted that end of dose pain is not BTCP; it
is caused by declining analgesic levels and indicates that
the ATC analgesic medication should be re-assessed77.
The pathophysiology of BTCP can be nociceptive,
neuropathic, or a combination of the two – often it is
the same as that of the underlying persistent pain.
Differentiating the causative mechanisms involved may
be difficult, but peripheral and/or central sensitization
may play a major role, initiated by mechanical stimuli,
changing chemical environments, and release of tumor
growth factors80. Although highly variable in character,
BTCP is typically rapid in onset, moderate to severe in
intensity, and relatively short in duration81. In 163 oncol-
ogy patients receiving palliative care who experienced
BTCP, 31% of episodes lasted515 minutes, 64% lasted
530 minutes, and 87% lasted560 minutes82. The mean
intensity was 7.3 on a 10 cm Visual Analogue Scale
(VAS), compared with 2.9 for persistent pain82. Other
studies have found the mean incidence to be four episodes
per day, with a mean duration of 30 minutes each (range
1–240 minutes)49, and the median time from onset to peak
intensity to be 3 minutes (range 1 second to 30 minutes)81.
Although BTCP follows a circadian pattern83, there is
considerable variability in duration and intensity from
one patient to another, and from one episode to another
in an individual patient.
BTCP is under-diagnosed and under-treated. In one
study of patients with advanced cancer who participated
in a palliative home care program, only 32% were
receiving medication for BTCP on admission to the
program, and 67% of the survivors 1 month later84.
There are various reasons for this. Firstly, BTCP is a
complex phenomenon which is dependent upon the
stage of the disease, the individual patient, and therapeutic
factors84. Secondly, the phenomenon is often not fully
understood by healthcare professionals so that patient
assessment is poor, and thirdly, there is often a reluctance
to prescribe opioids because of cultural or regulatory
factors, or concerns about side effects.
Moreover, even when BTCP is treated, the most
appropriate analgesic is not always prescribed. For exam-
ple, one study reported that the median time to peak inten-
sity of pain was 10 minutes (range 51 minute to 240
minutes) and the median duration of untreated episodes
was 60 minutes (range 51 minute to 360 minutes),
although the variability between patients was consider-
able85. Many patients, however, are treated with oral
opioids, for which the onset of analgesia takes at least
20–30 minutes and the peak effect is not experienced for
60–90 minutes86. Ideally, treatments for BTCP should
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have a rapid onset, short duration (1–2 hours), and suffi-
cient analgesic potency to relieve severe pain. Intravenous
or subcutaneous patient-controlled analgesia (PCA)
pumps come close to matching these criteria for hospita-
lized patients, but may not be practical for outpatients76.
Transmucosal rapid-onset opioids (fast-acting fentanyl
formulations) – such as oral fentanyl citrate (OTFC)
sublingual tablets87, the effervescent fentanyl buccal
tablet (FBT)88,89 and the intranasal fentanyl spray
(INFS)90,91 – utilize novel formulations to produce an
onset of analgesia often 15 minutes, making them
suitable for BTCP episodes with a rapid or unpredictable
onset. Maximum plasma concentrations are reached after
median times of 91 minutes (OTFC)89, 30–60 minutes
(transmucosal fentanyl tablets)92, 47 minutes (FBT)89
and 12–15 minutes (INFS)91. Fentanyl is highly potent
because of its lipophilicity and has no ceiling effect, i.e.
analgesia is proportional to the dose. When used to treat
BTCP, OTFC gives lower pain intensity scores and higher
pain relief scores than placebo and morphine at all time
points93. Similarly, randomized clinical trials have shown
FBT and INFS to be efficacious and well tolerated, with a
rapid onset of analgesia (within 10 minutes) and sustained
effect88,90,91. A systematic review of the use of opioids for
managing breakthrough pain in patients with cancer found
that transmucosal and parenteral opioids were equally
effective after 30minutes94, but one study which compared
OTFC with oral morphine found the latter to be an infer-
ior comparator95.
These properties have been taken into consideration by
recent guidelines, such as those produced by the European
Association for Palliative Care70. These state ‘‘In some
cases the buccal or intranasal fentanyl preparations are
preferable to immediate-release oral opioids because of
more-rapid onset of action and shorter duration of effect.
Additionally, the data permit a weak recommendation
that immediate-release formulations of opioids with short
half-lives should be used to treat pre-emptively predictable
episodes of breakthrough pain in the 20–30min preceding
the provoking manoeuvre.’’ The different fentanyl formu-
lations vary in pharmacokinetic properties and ease of use,
but all of them have a rapid onset and a relatively short
duration of analgesia. It should be noted that fast-acting
fentanyl formulations are only indicated for the treatment
of BTCP, and not as supplemental opioid therapy to
address circadian variations in pain intensity.
Consensus point
Fast-acting transmucosal fentanyl formulations are
considered a more appropriate choice for treating break-
through cancer pain with a rapid or unpredictable onset.
Chemotherapy-induced neuropathic pain
Chemotherapy-induced peripheral neuropathy (CIPN) is
a dose-limiting adverse effect of many chemotherapeutic
agents that affects 30–40% of patients receiving chemo-
therapy96. The incidence and severity depend upon the
type of cytotoxic drug(s), duration of administration,
cumulative dose, pharmacogenetics and presence of any
pre-existing peripheral neuropathy. Classes of agent
which can cause CIPN include platinum compounds,
taxanes, vinca alkaloids, thalidomide and bortezomib.
The intensity of pain is generally mild, with other
symptoms being more prominent, but it may be debilitat-
ing and reduce the quality of life of the patient. Recent
research indicates that satellite glial cells in dorsal root
ganglia are activated by cytotoxic agents, which leads to
increased gap junction-mediated coupling between these
cells and lowering of the pain threshold97.
The precise mechanism by which platinum compounds
induce CIPN remains unclear96. Neuropathy due to
cisplatin is usually reversible, typically appears 3–6
months after treatment starts and continues after discon-
tinuation of treatment. Symptoms are predominantly
sensory and include paresthesias, loss of vibration sense,
and decreased tendon reflexes96. Between 85% and 95% of
patients receiving oxaliplatin develop sensory neuropathy,
which presents as two different types of neurotoxicity98.
Shortly after infusion, most recipients develop an acute,
mainly cold-triggered neuropathy with distal paresthesias,
dysesthesias, and mild muscle contractions of the hands,
feet and perioral region96. This is followed by a chronic
sensory neuropathy with diminished or absent propriocep-
tion, vibration, touch, two-point discrimination, sharp/
dull discrimination, temperature, and touch/pain, typically
in a stocking-glove distribution96,99. In approximately
one-third of patients, symptoms disappear completely in
6–8 months.
In some patients receiving the taxane paclitaxel, a
cumulative, dose-dependent, painful neuropathy with
burning pain and hyperalgesia develops 24 to 72 hours
after administration100. Docetaxel produces CIPN much
less frequently than paclitaxel (1–9% vs. 30%)96, with
mild symptoms that usually disappear spontaneously after
discontinuation. Vinca alkaloids, of which vincristine is
the most toxic, induce alterations in the cellular microtu-
buli structure and disrupt the axonal flow96, causing a
painful sensory neuropathy and, in some patients, auto-
nomic dysfunction. The changes produced are usually
reversible on discontinuation, but recovery may be slow.
Other chemotherapeutic agents which may cause CIPN
include thalidomide and bortezomib.
Any candidate chemoprotective agent must fulfill
certain criteria: it must prevent or mitigate the CIPN
associated with chemotherapy without interfering with
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the antitumor activity of cytotoxic agents, and be devoid
of significant toxicity itself101. In a prospective, rando-
mized, double-blind, placebo-controlled crossover trial,
the serotonin–norepinephrine reuptake inhibitor duloxe-
tine significantly reduced the average pain score (mean
decrease 1.06 vs. 0.34 for placebo; p¼ 0.03) in patients
with painful CIPN following paclitaxel, other taxane, or
oxaliplatin treatment102. A similar study evaluated venla-
faxine for the prevention and relief of acute neurotoxicity
caused by oxaliplatin, and found this agent significantly
reduced symptoms compared with placebo (full relief
achieved by 31.3% vs. 5.3%; p¼ 0.03), whilst having an
acceptable toxicity profile103. Topical treatment with a
baclofen/amitriptyline/ketamine gel has demonstrated a
trend for improving CIPN symptoms – without evident
systemic toxicity – in a double-blind, randomized, pla-
cebo-controlled clinical trial104, but further research is
needed with higher doses. Promising results have also
been obtained in a pilot study of patient-specific cutaneous
electrostimulation in patients with CIPN following treat-
ment with taxanes, platinum drugs or bortezomib105.
The mean NRS pain score fell by 59% over the course of
10 days’ treatment (p50.0001), and a reduction of420%
was achieved by 94% of the patients (p50.0001)105.
Tricyclic antidepressants are often used to treat CIPN
and have been reported to relieve the paresthesia asso-
ciated with peripheral neuropathies. However, in a phase
III study to evaluate the alleviation of symptoms of cis-
platin-induced CIPN, nortriptyline increased patients’
hours of sleep but its effect on paresthesia was modest at
best, and there was no significant improvement in quality
of life or daily activities106. Similar results have been
obtained for amitriptyline107.
At the present time, preventative treatment should
be limited to patients at high risk of developing CIPN
(e.g. with diabetes, hypothyroidism, or a diagnosed
neuropathy) but this may change as more data are acquired
on potential agents such as TRPA1 (ankyrin) antagonists,
topical menthol, and antioxidants such as acetyl-
L-carnitine108–110.
Pain-related problems after cancer
Increasing numbers of patients are clear of cancer follow-
ing treatment, but often experience chronic pain syn-
dromes on the completion of treatment. Others are not
cured, but remain in a chronic, stable disease state for
many years. There is a lack of scientific evidence and
clinical guidelines for the management of these patients,
and optimal pain relief is hindered by barriers such as fear
of side effects, lack of professional knowledge of pain
management, lack of timely access to pain medication
and fear of addiction.
Various studies have estimated the prevalence of opioid
addiction in cancer patients to be between 0% and
7.7%111. The literature suggests that there is no single
predictor or tool capable of identifying patients likely to
misuse opioid medication, but certain patient characteris-
tics such as younger age, anxiety, fatigue and depression are
associated with greater risk112. Known risk factors should
be identified and monitored in order to detect misuse; for
example, by completing a Screener for Opioid Assessment
for Patients with Pain–Short Form (SOAPP–SF), estab-
lishing an opioid agreement and obtaining a
psychological evaluation112. However, it is difficult to
differentiate between inadequate analgesia (pseudoaddic-
tion), addiction, and use of opioids as an emotional coping
strategy113. Misuse increases the complexity of pain man-
agement, and unchecked addiction can lead to impaired
quality of life, decreased pain control, and caregiver
stress114. The risk of abuse may be greater for fast-acting
fentanyls than other formulations, owing to their rapid
onset of effect. Many hospice and palliative care phys-
icians report having had very little training in this field,
and survey results suggest that additional postgraduate
training focusing on opioid misuse might prove
beneficial113.
Pain management programs which take cognitive and
behavioral principles into account are the treatment of
choice, delivered by a multidisciplinary team working in
an interdisciplinary way115. This team should include a
pain specialist as well as a clinical psychologist, pain
should be taken into consideration from the beginning of
treatment, and team members should be closely
acquainted with each others’ roles and responsibilities.
Conclusions
Pain is the most common reason for consulting a health-
care professional that leads to a cancer diagnosis and its
effect on patients’ quality of life can be devastating, but the
treatment of cancer pain is often suboptimal. Almost
three-quarters of cancer patients experience pain, but
almost a quarter of those with moderate to severe pain
do not receive any analgesic medication and more than a
fifth are never, or only occasionally, asked about
their pain.
General principles for treating cancer pain include the
immediate relief of acute pain and preventing the devel-
opment of chronic pain. A multidisciplinary approach and
the choice of an appropriate pharmacological agent are
vital. Two particular challenges are BTCP and CIPN.
Treatments for BTCP should have a rapid onset, short
duration, and sufficient analgesic potency to relieve
severe pain – fast-acting fentanyl formulations meet
these criteria and are suitable for BTCP episodes with a
rapid or unpredictable onset. CIPN is a dose-limiting
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adverse effect of many chemotherapeutic agents. Several
potential neuroprotective agents have been investigated,
and duloxetine or venlafaxine significantly reduce CIPN
symptoms, but preventative treatment should currently be
limited to patients at high risk of developing the condition.
Addressing the unmet needs of cancer pain patients will
depend largely upon improving medical education, both at
undergraduate and postgraduate level. There should be
greater emphasis upon pain management at undergraduate
level116, a change of focus from symptom control to mech-
anism-based, multi-modal therapy, and more encourage-
ment for healthcare professionals to participate in
Continuing Medical Education related to pain
and analgesia, such as the PAIN EDUCATION
Program which is an integral part of the CHANGE
PAIN initiative.
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